Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q1 EPS of ($0.62), $0.12 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $10 million versus the consensus estimate of $111.11 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.